It concluded that sotrovimab can be used to treat confirmed COVID-19 in adults and adolescents (aged twelve years and above and weighing at least 40 kilograms (88 lb)) who do not require supplemental oxygen and who are at risk of progressing to severe COVID-19.
Research
Sotrovimab is being evaluated in the following clinical trials:
Clinical trial number NCT04545060 for "COMET-ICE" at ClinicalTrials.gov
Clinical trial number NCT04779879 for "COMET-PEAK" at ClinicalTrials.gov
Clinical trial number NCT04501978 for "ACTIV-3-TICO" at ClinicalTrials.gov
Clinical trial number NCT04634409 for "BLAZE-4" at ClinicalTrials.govIn March 2022, Australian virologists observed that sotrovimab may cause a drug-resistant mutation. References
External links
"Sotrovimab". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT04545060 for "VIR-7831 for the Early Treatment of COVID-19 in Outpatients (COMET-ICE)" at ClinicalTrials.gov
Australian Public Assessment Report: Sotrovimab. Therapeutic Goods Administration (TGA) (Report). 20 August 2021.